HCMN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a sizable equity base provide HUTCHMED with financial flexibility to fund drug development, regulatory work, and commercialization without heavy debt servicing demands. This strengthens resilience while the company works through uneven operating results.
Integrated Commercial And Partnered ModelCombining commercial product sales with licensing, milestones, cost reimbursements, and royalties gives HUTCHMED multiple routes to monetize its pipeline. This model can broaden the company’s revenue base and let global partners support development and market access.
Positive Recent Revenue TrendModest trailing-twelve-month revenue growth indicates that HUTCHMED’s marketed products and commercial activities are generating some top-line expansion. If sustained, this provides a foundation for absorbing development costs and improving operating leverage as products mature.
Bears Say
Negative Core ProfitabilityPersistent negative EBIT and EBITDA margins show that core operations are not yet producing sustainable operating profits. Gross-profit compression further limits the ability to convert revenue into funding for research, commercialization, and future pipeline expansion.
Volatile Free Cash FlowLarge swings in free cash flow make internal funding less predictable even though the latest trailing period is positive. This variability can complicate development planning and capital allocation, particularly when clinical and regulatory spending rises.
Earnings Quality RiskStrong reported net income alongside negative operating profit raises questions about how repeatable current earnings are from the underlying business. Reliance on non-operating items can make results more volatile and obscure progress toward durable operational profitability.
HUTCHMED News
HCMN FAQ
What was HUTCHMED’s price range in the past 12 months?
Currently, no data Available
What is HUTCHMED’s market cap?
HUTCHMED’s market cap is $38.65B.
When is HUTCHMED’s upcoming earnings report date?
HUTCHMED’s upcoming earnings report date is Mar 04, 2027 which is in 170 days.
How were HUTCHMED’s earnings last quarter?
HUTCHMED released its earnings results on Jul 30, 2026. The company reported $1.691 earnings per share for the quarter, missing the consensus estimate of $2.452 by -$0.761.
Is HUTCHMED overvalued?
According to Wall Street analysts HUTCHMED’s price is currently Undervalued.
Does HUTCHMED pay dividends?
HUTCHMED does not currently pay dividends.
What is HUTCHMED’s EPS estimate?
HUTCHMED’s EPS estimate is 3.55.
How many shares outstanding does HUTCHMED have?
HUTCHMED has 174,467,030 shares outstanding.
What happened to HUTCHMED’s price movement after its last earnings report?
HUTCHMED reported an EPS of $1.691 in its last earnings report, missing expectations of $2.452. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of HUTCHMED?
Currently, no hedge funds are holding shares in MX:HCMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HUTCHMED Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$274.55 (― Upside)
$274.55 (― Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.68%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
HUTCHMED
HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.
HCMN Company Deck
HCMN Earnings Call
Q2 2026
0:00 / 0:00